Is ALKS a Buy? What to Consider in 2026

Last updated July 2026

Short answer

The bull case for Alkermes plc (ALKS) rests on Orexin pipeline optionality: Alixorexton (formerly ALKS 2680) is a once-daily orexin 2 receptor agonist that delivered positive Phase 2 data in narcolepsy types 1 and 2 and entered a Phase 3 (Brilliance) program in 2026 with FDA Breakthrough Therapy designation. Revenue (TTM) is ~$1.5B. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Clinical outcomes are binary: a Phase 3 setback for alixorexton would remove the main growth thesis and could sharply reset the valuation. Whether ALKS is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.

Alkermes plc is an Ireland-domiciled, Nasdaq-listed biopharmaceutical company focused on the central nervous system. Its commercial base spans Vivitrol (extended-release naltrexone for alcohol and opioid dependence), Aristada (long-acting injectable for schizophrenia), and Lybalvi (an oral olanzapine/samidorphan combination for schizophrenia and bipolar I). In February 2026 it acquired Avadel Pharmaceuticals, adding Lumryz, a once-nightly sodium oxybate for narcolepsy, which broadened the portfolio into sleep medicine. The company is profitable on an adjusted basis and generates meaningful operating cash flow, which it uses to fund its pipeline rather than relying heavily on dilution. The investment picture is a blend of steady product cash flow and pipeline optionality. The marketed drugs throw off enough revenue to keep Alkermes self-funding, but several face maturing growth curves and eventual generic or loss-of-exclusivity pressure. The upside case centers on the orexin franchise, led by alixorexton (formerly ALKS 2680), an orexin 2 receptor agonist that posted positive Phase 2 results in narcolepsy and entered a Phase 3 program in 2026, backed by FDA Breakthrough Therapy designation. Success there could reposition Alkermes as a sleep-disorder leader, while a clinical miss would leave the story leaning on aging franchises.

What's the case for buying ALKS?

1. Orexin pipeline optionality

Alixorexton (formerly ALKS 2680) is a once-daily orexin 2 receptor agonist that delivered positive Phase 2 data in narcolepsy types 1 and 2 and entered a Phase 3 (Brilliance) program in 2026 with FDA Breakthrough Therapy designation. Follow-on orexin candidates (ALKS 7290, ALKS 4510) are in early human studies. This franchise is the primary long-term value driver and the main source of both upside and binary risk.

2. Cash-generative commercial base

Vivitrol, Aristada, and Lybalvi together produce over a billion dollars in annual proprietary product sales, and the portfolio is profitable on an adjusted EBITDA basis. This self-funding structure lets Alkermes finance clinical development and business development without heavy reliance on equity raises.

3. Avadel/Lumryz sleep expansion

The February 2026 acquisition of Avadel added Lumryz, a once-nightly sodium oxybate for narcolepsy, giving Alkermes an existing commercial foothold in sleep ahead of a potential alixorexton launch. Management guided Lumryz toward roughly $315 to $335 million of net sales in 2026, and the drug creates commercial and label-expansion synergies with the orexin program.

4. Portfolio life-cycle management

Lybalvi remains a growth product within the schizophrenia and bipolar franchise, while Vivitrol and Aristada are more mature. Ongoing label work and the sodium-oxybate idiopathic-hypersomnia effort aim to extend the revenue base and smooth the transition toward pipeline-driven growth.

What are the risks to ALKS?

Clinical outcomes are binary: a Phase 3 setback for alixorexton would remove the main growth thesis and could sharply reset the valuation. Legacy franchises face patent expiries and generic competition (notably Vivitrol and the schizophrenia injectables), which can erode the cash base that funds the pipeline. The Avadel deal added integration risk and litigation exposure tied to Lumryz's competitive position against Jazz Pharmaceuticals' oxybate products. Concentration in central-nervous-system and sleep indications leaves Alkermes exposed to specific payer, pricing, and regulatory dynamics, and as an Ireland-domiciled company it also carries tax and cross-border considerations. Any of these can drive outsized share-price swings around data and regulatory catalysts.

How is ALKS valued? (as of July 2026)

Price

$52.72

Market cap

$8.79B

P/E (TTM)

58.58

Forward P/E

32.19

Price / book

5.01

Beta

0.29

52-week range

$25.17 to $55.67

Snapshot for ALKS as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.

Revenue (TTM): ~$1.5B
Q1 2026 revenue: ~$393M (+28% YoY)
Q1 2026 adj. EBITDA: ~$80M
Q1 2026 GAAP net loss: ~$(67)M
Market cap: ~$8.5B
2026 top-product guidance: Vivitrol ~$460-480M, Lybalvi ~$380-400M

First-quarter 2026 revenue of roughly $393 million rose about 28% year over year, helped by product growth and the newly consolidated Lumryz, though the quarter showed a GAAP net loss partly reflecting Avadel deal costs. Adjusted EBITDA of around $80 million underscores the underlying profitability of the marketed portfolio. At an approximately $8.5 billion market cap on roughly $1.5 billion of trailing revenue, the market is pricing in meaningful pipeline value beyond the current product base.

How do you decide if ALKS is a buy?

Rather than asking whether ALKS is a buy in the abstract, it tends to help to answer four questions:

Thesis: do you believe the case above, and is it still true today?
Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
Overlap: check whether you already hold ALKS indirectly through an index or sector ETF before adding more.

For the full picture, see the ALKS stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about ALKS against your real portfolio and see your actual exposure before deciding.

The bottom line on ALKS

The bottom line: Alkermes plc's story right now is Orexin pipeline optionality, with revenue (ttm) at ~$1.5B. If you believe that narrative continues, the call is about sizing ALKS sensibly and checking overlap with what you own; if you doubt it (the risk: clinical outcomes are binary: a Phase 3 setback for alixorexton would remove the main growth thesis and could sharply reset the valuation.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.

Build a basket around ALKS with Walnut

Use Alkermes plc as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.

Create a free Walnut account

FAQ

Is ALKS a good stock to buy right now?

The case for Alkermes plc right now is Orexin pipeline optionality, with revenue (ttm) at ~$1.5B. If you believe that thesis holds, ALKS is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is clinical outcomes are binary: a Phase 3 setback for alixorexton would remove the main growth thesis and could sharply reset the valuation. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.

What does Alkermes plc do?

Alkermes plc is an Ireland-domiciled, Nasdaq-listed biopharmaceutical company focused on the central nervous system.

What are the main risks of ALKS?

What does Alkermes do?

Alkermes is a commercial-stage biopharmaceutical company focused on the central nervous system. It sells marketed neuroscience drugs for addiction, schizophrenia, and bipolar disorder, added a narcolepsy product through its 2026 Avadel acquisition, and is developing an orexin pipeline led by alixorexton.

What are Alkermes' main products?

Its core marketed products are Vivitrol (alcohol and opioid dependence), Aristada (schizophrenia), and Lybalvi (schizophrenia and bipolar I). The February 2026 Avadel deal added Lumryz, a once-nightly sodium oxybate for narcolepsy.

Is Alkermes profitable?

Alkermes is profitable on an adjusted basis, reporting roughly $80 million of adjusted EBITDA in the first quarter of 2026. It did post a GAAP net loss that quarter, partly reflecting costs tied to the Avadel acquisition, but the marketed portfolio generates positive operating cash flow.

What is alixorexton (ALKS 2680)?

Alixorexton, formerly ALKS 2680, is a once-daily orexin 2 receptor agonist in development for narcolepsy and idiopathic hypersomnia. It produced positive Phase 2 results, holds FDA Breakthrough Therapy designation in narcolepsy type 1, and entered a Phase 3 program in 2026.

Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell ALKS; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.